Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 15/20 | 0.84 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.73 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26648341 | 1.00 | BCL2 (0.84) | BCL2HDAC1HDAC6 | |
| SCHEMBL31450972 | 0.99 | BCL2 (0.82) | BCL2HDAC1HDAC6 | |
| SCHEMBL26647909 | 0.99 | BCL2 (0.82) | BCL2HDAC1HDAC6 | |
| SCHEMBL26648300 | 0.97 | BCL2 (0.81) | BCL2HDAC1HDAC6 | |
| SCHEMBL26648251 | 0.97 | BCL2 (0.81) | BCL2HDAC1HDAC6 | |
| SCHEMBL31450898 | 0.97 | BCL2 (0.81) | BCL2HDAC1HDAC6 | |
| SCHEMBL31451009 | 0.97 | BCL2 (0.81) | BCL2HDAC1HDAC6 | |
| SCHEMBL26647903 | 0.96 | BCL2 (0.85) | BCL2HDAC1HDAC6 | |
| SCHEMBL31451053 | 0.96 | BCL2 (0.85) | BCL2HDAC1HDAC6 | |
| SCHEMBL31450794 | 0.95 | BCL2 (0.83) | BCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4522154-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | BCL2L2, BCL2A1, BCL2L1 | BCL2 4/4885HDAC1 620/4885HDAC6 1205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.